0000000000020652

AUTHOR

Marco Presta

0000-0002-4398-8376

showing 4 related works from this author

Evidence for characteristic vascular patterns in solid tumours: quantitative studies using corrosion casts

1999

The vascular architecture of four different tumour cell lines (CaX, CaNT, SaS, HEC-1B) transplanted subcutaneously in mice was examined by means of microvascular corrosion casting in order to determine whether there is a characteristic vascular pattern for different tumour types and whether it differs significantly from two normal tissues, muscle and gut. Three-dimensional reconstructed scanning electron microscope images were used for quantitative measurements. Vessel diameters, intervessel and interbranch distances showed large differences between tumour types, whereas the branching angles were similar. In all tumours, the variability of the vessel diameters was significantly higher than …

Cancer ResearchPathologymedicine.medical_specialtyAngiogenesisTransplantation Heterologousvascular patternNormal tissueMice NudeAdenocarcinomaBiologyCorrosion CastingVascular architectureMiceMicroscopyTumor Cells CulturedmedicineAnimalsHumansmicrovascular corrosion castingtumourCarcinomaRegular ArticleNeoplasms ExperimentalAnatomymedicine.diseaseEndometrial NeoplasmsTransplantationxenograftsOncologyVascular networkrodentsMice Inbred CBAMicroscopy Electron ScanningFemaleSarcoma ExperimentalSarcomaCorrosion CastingNeoplasm TransplantationBritish Journal of Cancer
researchProduct

Synthesis, Structural Elucidation, and Biological Evaluation of NSC12, an Orally Available Fibroblast Growth Factor (FGF) Ligand Trap for the Treatme…

2016

NSC12 is an orally available pan-FGF trap able to inhibit FGF2/FGFR interaction and endowed with promising antitumor activity. It was identified by virtual screening from a NCI small molecule library, but no data were available about its synthesis, stereochemistry, and physicochemical properties. We report here a synthetic route that allowed us to characterize and unambiguously identify the structure of the active compound by a combination of NMR spectroscopy and in silico conformational analysis. The synthetic protocol allowed us to sustain experiments aimed at assessing its therapeutic potential for the treatment of FGF-dependent lung cancers. A crucial step in the synthesis generated a c…

Models Molecular0301 basic medicineLung NeoplasmssynthesisFGF Lung cancer growth factor chemical characterization synthesisIn silicoAdministration OralAntineoplastic AgentsPharmacologyFibroblast growth factorMiceStructure-Activity Relationship03 medical and health sciences0302 clinical medicineIn vivoDrug DiscoveryTumor Cells CulturedAnimalsHumansFGFStructure–activity relationshipCell ProliferationDose-Response Relationship DrugMolecular Structurechemical characterizationCell growthChemistrygrowth factorLigand (biochemistry)Small moleculeCell biologyFibroblast Growth FactorsCholesterol030104 developmental biologyFibroblast growth factor receptor030220 oncology & carcinogenesisMolecular MedicineDrug Screening Assays AntitumorLung cancerJournal of Medicinal Chemistry
researchProduct

Long Pentraxin 3-Mediated Fibroblast Growth Factor Trapping Impairs Fibrosarcoma Growth

2018

Fibrosarcomas are soft tissue mesenchymal tumors originating from transformed fibroblasts. Fibroblast growth factor-2 (FGF2) and its tyrosine-kinase receptors (FGFRs) play pivotal roles in fibrosarcoma onset and progression, FGF2 being actively produced by fibroblasts in all stages along their malignant transformation to the fibrosarcoma stage. The soluble pattern recognition receptor long pentraxin-3 (PTX3) is an extrinsic oncosuppressor whose expression is reduced in different tumor types, including soft tissue sarcomas, via hypermethylation of its gene promoter. PTX3 interacts with FGF2 and other FGF family members, thus acting as a multi-FGF antagonist able to inhibit FGF-dependent neov…

0301 basic medicineCancer ResearchFGF; FGF-trap; FGFR; fibrosarcoma; long pentraxin-3Fibroblast growth factorlcsh:RC254-282Malignant transformation03 medical and health sciences0302 clinical medicinemedicineFGFFibrosarcomaFibroblastReceptorneoplasmsOriginal ResearchFGF-trapintegumentary systemChemistryFGFRMesenchymal stem cellPTX3medicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens030104 developmental biologymedicine.anatomical_structurelong pentraxin-3OncologyFibroblast growth factor receptor030220 oncology & carcinogenesisCancer researchfibrosarcomaFrontiers in Oncology
researchProduct

Shedding of Membrane Vesicles Mediates Fibroblast Growth Factor-2 Release from Cells

2003

Fibroblast growth factor-2 (FGF-2), a polypeptide with regulatory activity on cell growth and differentiation, lacks a conventional secretory signal sequence, and its mechanism of release from cells remains unclear. We characterized the role of extracellular vesicle shedding in FGF-2 release. Viable cells released membrane vesicles in the presence of serum. However, in serum-free medium vesicle shedding was dramatically down-regulated, and the cells did not release FGF-2 activity into their conditioned medium. Addition of serum to serum-starved cells rapidly induced intracellular FGF-2 clustering under the plasma membrane and into granules that colocalized with patches of the cell membrane …

SerumFGF-2 extracellular vesiclesBiologyFibroblast growth factorBiochemistryCulture Media Serum-FreeSettore MED/13 - EndocrinologiaCell Line; Tumor; Endothelial Cells; Fibroblast Growth Factor 2; Secretory VesiclesCell LineCell membraneSettore BIO/13 - Biologia ApplicataCell Line TumorSettore BIO/10 - BiochimicamedicineHumansProtein IsoformsFibroblastMolecular BiologyTumorSecretory VesiclesVesicleCell MembraneEndothelial CellsCell BiologyExtracellular vesicleSecretory VesicleCell biologyKineticsmedicine.anatomical_structureMicroscopy FluorescenceCell cultureFibroblast Growth Factor 2IntracellularJournal of Biological Chemistry
researchProduct